Trial Profile
A Randomized Phase II Study of Multipeptide Vaccination With or Without IL-12, Then Combined With Regulatory T Cell Depletion Using Daclizumab in Patients With Metastatic Melanoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Daclizumab (Primary) ; Interleukin-12 (Primary) ; MelanA gp100 MAGE3 NA174 peptide vaccine (Primary) ; Montanide ISA-51; Subunit vaccines; Subunit vaccines
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 31 Aug 2016 Status changed from active, no longer recruiting to discontinued.
- 15 Aug 2012 Planned End Date 1 Dec 2013 added as reported by ClinicalTrials.gov.
- 01 Mar 2011 New trial record